These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 24555231)
1. [Pharmacokinetic evaluation of a new prolonged dosage form of afobazole in comparison to commercially available tablets]. Bochkov PO; Litvin AA; Kolyvanov GB; Zherdev VP; Blynskaia EV; Grushevskaia LN; Illarionov AA Eksp Klin Farmakol; 2013; 76(11):33-5. PubMed ID: 24555231 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of tissue availability for afobazole and compound M-11. Viglinskaya AO; Bastrygin DV; Kolyvanov GB; Litvin AA; Zherdev VP; Mozhaeva TY Bull Exp Biol Med; 2010 Sep; 149(3):318-9. PubMed ID: 21246091 [TBL] [Abstract][Full Text] [Related]
7. [In vivo study of the pharmacokinetic interaction of afobazole and losartan (cytochrome CYP2C9 substrate)]. Gribakina OG; Kolyvanov GB; Litvin AA; Zherdev VP; Seredin SB Eksp Klin Farmakol; 2013; 76(3):35-7. PubMed ID: 23767102 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic and analgesic properties of tabletized dosage form of RU-1205-new imidazobenzimidazole derivative with kappa agonist activity]. Spasov AA; Smirnova LA; Grechko OIu; Rashchenko AI; Shtareva DM; Anisimova VA Eksp Klin Farmakol; 2014; 77(7):27-30. PubMed ID: 25322651 [TBL] [Abstract][Full Text] [Related]
9. [In vivo evaluation of the metabolic ratio of CYP2C9 and CYP1A2 drug markers after administration of afobazole in comparison to standard inducers and inhibitors of cytochromes]. Novitskaia IaG; Gribakina OG; Kolyvanov GB; Zherdev VP; Smirnov VV; Seredenin SB Eksp Klin Farmakol; 2013; 76(11):36-9. PubMed ID: 24555232 [TBL] [Abstract][Full Text] [Related]
10. Tissue availability of afobazole and its major metabolites in rats. Viglinskaya AO; Kolyvanov GB; Litvin AA; Kravtsova OY; Zherdev VP; Seredenin SB Bull Exp Biol Med; 2007 May; 143(5):593-4. PubMed ID: 18239776 [TBL] [Abstract][Full Text] [Related]
12. Excretion of afobazole and its metabolites with urine and feces in rats. Viglinskaya AO; Kolyvanov GB; Litvin AA; Zherdev VP; Seredenin SB Bull Exp Biol Med; 2008 Apr; 145(4):440-2. PubMed ID: 19110588 [TBL] [Abstract][Full Text] [Related]
13. [Influence of anxiolytic afobazole on amygdalar neuronal activity and behavior of rabbits in emotionally negative situations]. Rysakova MP; Pavlova IV Zh Vyssh Nerv Deiat Im I P Pavlova; 2011; 61(3):351-64. PubMed ID: 21861391 [TBL] [Abstract][Full Text] [Related]
14. [EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450]. Gribakina OG; Kolyvanov GB; Litvin AA; Smirnov VV; Shevchenko RV; Zherdev VP Eksp Klin Farmakol; 2015; 78(12):18-22. PubMed ID: 27051923 [TBL] [Abstract][Full Text] [Related]
15. [Effect of afobazole on the psychophysiological state of healthy volunteers]. Bogdan NG; Kolotilinskaia NV; Nadorov SA; Iarkova MA; Badyshtov BA Eksp Klin Farmakol; 2011; 74(8):8-12. PubMed ID: 22232907 [TBL] [Abstract][Full Text] [Related]
16. [Cerebrovascular effects of afobazole under conditions of combined disorders of cerebral and coronary circulation]. Mirzoian RS; Khaĭlov NA; Gan'shina TS Eksp Klin Farmakol; 2010 May; 73(5):2-7. PubMed ID: 20597361 [TBL] [Abstract][Full Text] [Related]
17. [Comparative study of the interoceptive effects of afobazole and diazepam]. Volkova AV; Kalinina TC; Voronina TA Eksp Klin Farmakol; 2010 Oct; 73(10):2-6. PubMed ID: 21254504 [TBL] [Abstract][Full Text] [Related]